Active, not recruitingPhase 2NCT04404881
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
Studying Hereditary hemorrhagic telangiectasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hanny Al-Samkari, MD
- Principal Investigator
- Hanny Al-Samkari, MDMassachusetts General Hospital
- Intervention
- Bevacizumab (Avastin®)(drug)
- Enrollment
- 33 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (1)
- Massachusetts General Hospital, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04404881 on ClinicalTrials.govOther trials for Hereditary hemorrhagic telangiectasia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07255846A Trial of TER-1754 in Patients With Hereditary Hemorrhagic TelangiectasiaTerremoto Biosciences Inc.
- ENROLLING BY INVITATIONNCT07445347Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia NetworkPoitiers University Hospital
- RECRUITINGPHASE1, PHASE2NCT06659640A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Alnylam Pharmaceuticals
- ACTIVE NOT RECRUITINGNCT07018401Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment StudyMassachusetts General Hospital
- ENROLLING BY INVITATIONNCT06261333Quality of Life in Patients With Hemorrhagic TelangiectasiaUniversity Hospital, Essen
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT03850964Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)Cure HHT
- RECRUITINGNANCT05641142Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic TelangiectasiaUniversity Hospital, Clermont-Ferrand
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05406362Assess Safety and Efficacy of VAD044 in HHT PatientsVaderis Therapeutics AG